“To Biologic or Not to Biologic?: The Question of Cost-Effectiveness”

As of 2018, the FDA had approved five biologics for the treatment of asthma – omalizumab, mepolizumab, reslizumab, benralizumab, and dupilumab. All five of these biologics are designated for the treatment of severe asthma in patients with a TH2-driven phenotype, either allergic or eosinophilic. In clinical trials, biologics have demonstrated efficacy to decrease the frequency of asthma exacerbations, unplanned health utilization including ED visits and hospitalizations, and chronic oral steroid use in severe asthmatic patients1.

http://bit.ly/2sRvUnp